Table 2.

Treatment administration.

	LeToHAIC group (n = 71)	Lenvatinib group (n = 86)	p-value
Study treatment, median (range)
HAIC cycle	4 (1–6)	–
Toripalimab cycle	8 (1–17)	–
Duration of lenvatinib, months	9.1 (1.4–16.6)	4.7 (0.9–16.4)
Number of patients who received subsequent treatments
HAIC	0	12	0.001
Resection	9	0	0.001
Ablation	3	0	0.18
Sorafenib	9	17	0.23
PD-1 antibody	15*	40	0.001
Regorafenib	20	39	0.03
Transarterial chemoembolization	13	16	0.96
Radiotherapy	8	5	0.22

^*Patient in the LeToHAIC group receive other PD-1 antibodies, such as nivolumab, pembrolizumab, sintilimab, camrelizumab.

HAIC, hepatic arterial infusion chemotherapy; LeToHAIC, lenvatinib, toripalimab plus HAIC; PD-1, programmed cell death protein-1.